CLIF-C AD Score Predicts Development of Acute Decompensations and Survival in Hospitalized Cirrhotic Patients.
Ascites
CLIF-C AD score
Liver cirrhosis
MELD score
Multiple organ failure
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
25
07
2020
accepted:
14
12
2020
pubmed:
4
1
2021
medline:
15
12
2021
entrez:
3
1
2021
Statut:
ppublish
Résumé
Patients with decompensated cirrhosis are at increased risk of mortality, even in absence of ACLF. The CLIF-C AD score (CLIF-C ADs) was proposed as a prognostic score but lacks sufficient validation. Our aim was to describe clinical characteristics and hospital evolution according to score groups and evaluate prognostic capability of CLIF-C ADs alone or in combination with other scores. Two hundred and sixty-six patients (55 ± 14 years, ascites in 63%, MELD 14 ± 5) were included, and classified as high, intermediate and low CLIF-C ADs in 13, 60 and 27% of cases. Development of new complications of cirrhosis during hospitalization and survival at 3 months were evaluated. Patients with high CLIF-C ADs had more severe systemic inflammation parameters and higher frequency of organ dysfunction. CLIF-C ADs ≥ 60, when compared to intermediate and low groups, was associated with higher incidence of complications of cirrhosis (90% vs 70% and 49%, p < 0.001) and lower survival (93%, 80% and 50%, p < 0.0001). In multivariate analysis, CLIF-C ADs, ascites and MELD were predictors of survival [(AUROC 0.76 (95% CI 0.69-0.83)]. Absence of ascites or MELD < 14 identified patients with intermediate CLIF-C ADs and good survival (89 and 84%, respectively). CLIF-C ADs predicts survival in cirrhotic patients with AD. High CLIF-C ADs is associated with higher frequency of organ dysfunction, increased risk of new complications of cirrhosis and high short-term mortality. On the contrary, individuals with low CLIF-C ADs, as well as those with intermediate score without ascites or with low MELD have excellent prognoses.
Sections du résumé
BACKGROUND AND AIMS
Patients with decompensated cirrhosis are at increased risk of mortality, even in absence of ACLF. The CLIF-C AD score (CLIF-C ADs) was proposed as a prognostic score but lacks sufficient validation. Our aim was to describe clinical characteristics and hospital evolution according to score groups and evaluate prognostic capability of CLIF-C ADs alone or in combination with other scores.
METHODS
Two hundred and sixty-six patients (55 ± 14 years, ascites in 63%, MELD 14 ± 5) were included, and classified as high, intermediate and low CLIF-C ADs in 13, 60 and 27% of cases. Development of new complications of cirrhosis during hospitalization and survival at 3 months were evaluated.
RESULTS
Patients with high CLIF-C ADs had more severe systemic inflammation parameters and higher frequency of organ dysfunction. CLIF-C ADs ≥ 60, when compared to intermediate and low groups, was associated with higher incidence of complications of cirrhosis (90% vs 70% and 49%, p < 0.001) and lower survival (93%, 80% and 50%, p < 0.0001). In multivariate analysis, CLIF-C ADs, ascites and MELD were predictors of survival [(AUROC 0.76 (95% CI 0.69-0.83)]. Absence of ascites or MELD < 14 identified patients with intermediate CLIF-C ADs and good survival (89 and 84%, respectively).
CONCLUSION
CLIF-C ADs predicts survival in cirrhotic patients with AD. High CLIF-C ADs is associated with higher frequency of organ dysfunction, increased risk of new complications of cirrhosis and high short-term mortality. On the contrary, individuals with low CLIF-C ADs, as well as those with intermediate score without ascites or with low MELD have excellent prognoses.
Identifiants
pubmed: 33389350
doi: 10.1007/s10620-020-06791-5
pii: 10.1007/s10620-020-06791-5
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
4525-4535Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.
Références
Sole C, Pose E, Sola E, Gines P. Hepatorenal syndrome in the era of acute kidney injury. Liver Int. 2018;38:1891–1901.
doi: 10.1111/liv.13893
Planas R, Montoliu S, Balleste B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385–1394.
doi: 10.1016/j.cgh.2006.08.007
Hernaez R, Sola E, Moreau R, Gines P. Acute-on-chronic liver failure: an update. Gut. 2017;66:541–553.
doi: 10.1136/gutjnl-2016-312670
Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144:1426–1437.
doi: 10.1053/j.gastro.2013.02.042
Shi Y, Yang Y, Hu Y, et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology. 2015;62:232–242.
doi: 10.1002/hep.27795
Kim TY, Song DS, Kim HY, et al. Characteristics and discrepancies in acute-on-chronic liver failure: need for a unified definition. PLoS ONE. 2016;11:e0146745.
doi: 10.1371/journal.pone.0146745
Bajaj JS, Vargas HE, Reddy KR, et al. Association between intestinal microbiota collected at hospital admission and outcomes of patients with cirrhosis. Clin Gastroenterol Hepatol. 2019;17:756-65.e3.
Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis. 2008;28:110–122.
doi: 10.1055/s-2008-1040325
Jalan R, Pavesi M, Saliba F, et al. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. J Hepatol. 2015;62:831–840.
doi: 10.1016/j.jhep.2014.11.012
Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49:2087–2107.
doi: 10.1002/hep.22853
Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding–unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. Hepatology. 2008;47:1764–1772.
doi: 10.1002/hep.22273
Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL special conference 2013. J Hepatol. 2014;60:1310–1324.
doi: 10.1016/j.jhep.2014.01.024
Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715–735.
doi: 10.1002/hep.27210
Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64:531–537.
doi: 10.1136/gutjnl-2014-308874
Solà E, Ginès P. Hypervolemic hyponatremia (liver). Front Horm Res. 2019;52:104–112.
doi: 10.1159/000493241
Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61:1038–1047.
doi: 10.1016/j.jhep.2014.06.012
Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281.
doi: 10.1111/j.1469-0691.2011.03570.x
Trebicka J, Fernandez J, Papp M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol. 2020;73:842–854.
doi: 10.1016/j.jhep.2020.06.013
Claria J, Stauber RE, Coenraad MJ, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology. 2016;64:1249–1264.
doi: 10.1002/hep.28740
Moreau R, Clària J, Aguilar F, et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. J Hepatol. 2020;72:688–701.
doi: 10.1016/j.jhep.2019.11.009
Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306:2594–2605.
doi: 10.1001/jama.2011.1829
Fernández J, Acevedo J, Wiest R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2018;67:1870–1880.
doi: 10.1136/gutjnl-2017-314240
Wong F. Clinical consequences of infection in cirrhosis: organ failures and acute-on-chronic liver failure. Clin Liver Dis (Hoboken). 2019;14:92–97.
doi: 10.1002/cld.813
Bossen L, Ginès P, Vilstrup H, Watson H, Jepsen P. Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascites. J Gastroenterol Hepatol. 2019;34:914–920.
doi: 10.1111/jgh.14558
Biselli M, Gitto S, Gramenzi A, et al. Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: which is the winner? Liver Transpl. 2010;16:964–973.
doi: 10.1002/lt.22093
Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–M156.
doi: 10.1093/gerona/56.3.M146
Shi Y, Shu Z, Sun W, et al. Risk stratification of decompensated cirrhosis patients by chronic liver failure consortium scores: classification and regression tree analysis. Hepatol Res. 2017;47:328–337.
doi: 10.1111/hepr.12751
Alexopoulou A, Vasilieva L, Mani I, Agiasotelli D, Pantelidaki H, Dourakis SP. Single center validation of mortality scores in patients with acute decompensation of cirrhosis with and without acute-on-chronic liver failure. Scand J Gastroenterol. 2017;52:1385–1390.
doi: 10.1080/00365521.2017.1369560
Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology. 2005;41:1282–1289.
doi: 10.1002/hep.20687
Bishay K, Tandon P, Fisher S, et al. Clinical factors associated with mortality in cirrhotic patients presenting with upper gastrointestinal bleeding. J Can Assoc Gastroenterol. 2020;3:127–134.
doi: 10.1093/jcag/gwy075